Omeros’ OMS302 reduces incidence of miosis during intraocular lens replacement in Phase 3 clinical trial

Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement (ILR). OMS302 is the company's proprietary Pharmacosurgery® product being developed for all ILR, including cataract surgery and refractive lens exchange. 

The analyses were presented by Steve Whitaker, M.D., Omeros' vice president of clinical development and chief medical officer on November 17 at the Annual American Academy of Ophthalmology (AAO) Meeting in New Orleans. The clinical data presented at the AAO meeting and shown below demonstrated that, in these clinical trials in which all patients received standard-of-care preoperative mydriatic topical drops, OMS302 reduced the occurrence of intraoperative pupil constriction. Intraoperative miosis is an important risk factor for surgical complications. As shown in the figure below, pupil constriction of at least 3 millimeters was common in control patients while constriction greater than 1 millimeter was uncommon in OMS302-treated patients.

"We are pleased with the recognition that the recent clinical data for OMS302 received from the ophthalmic community during the AAO annual meetings," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "Ophthalmologists continue to appreciate the potential clinical benefits of OMS302, and we look forward to the drug's expected commercial launch in 2014."

Source:

Omeros Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Scientists identify potential biomarkers to predict COVID-19 outcomes